A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Health Canada has issued a recall notice for compounded drugs containing semaglutide, which is a key component in popular ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

A new report finds half of adults in the United States could be eligible for popular weight loss drugs. KYW medical editor Dr ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...